PATENT CLAIM ANALYSIS

Application Number: 15744243
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["435", "006140"]

Abstract:
A method of selecting a subject suffering from a cancer for a therapeutic regimen of administration of a pharmaceutical composition comprising an effective amount of an FGFR inhibitor is described, which method comprises (1) the taking of a tumor or liquid biopsy from the subject; (2) determination of the level of expression of any or all of FGFR1, FGFR2 and FGFR3, and (3) comparison of the determined level of expression of at least one of FGFR1, FGFR2 and FGFR3 with a pre-established threshold value, and declaring the subject eligible for the therapeutic regimen if the determined level exceeds the threshold value. The invention also relates to a method of personalized cancer therapy comprising selection of a subject by the above-described method and subjecting the subject to a therapeutic regimen that comprises administration of a pharmaceutical composition comprising an effective amount of an FGFR inhibitor.

Claim (Index 11):
The method of  claim 2 , wherein the cancer is esophageal squamous-cell carcinoma and the pre-established threshold level of expression of FGFR1 corresponds to any level from the 44% to the 84% cutoff level of expression for FGFR1, corresponding to expression levels relative to the median of levels of mRNA expression of a set of 16 reference genes measured by the nCounter Gene Expression Assay from 0.104 to 1.362 for FGFR1, the 16 reference genes being ACTB, ALAS1, CLTC, MRPL19, RPL19, RPLP0, SF3A1, TBP, TUBB, c1orf43 exon 1, c1orf43 exon 2, CHMP2A exon 3, EMC7 exon 5, EMC7 exon 3, GPI exon 4 and GPI exon 6.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 86.0
- Lexical Diversity: 2.16438
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12304638', '14048841', '13612044', '13509068', '12652720']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6363579487446153
- 35 USC 102 Novelty (BERT): 0.5168963315427639
- Combined Prediction Score: 0.6244117870244302
- Mean Citation Score: 300.951362
- Max Citation Score: 313.2089200000001
- Similarity Product: 218.36349048332696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test